Novavax, Inc. (NVAX)
| Previous close | 3.8900 |
| Open | 3.8900 |
| Bid | 3.9400 x 3200 |
| Ask | 3.9900 x 700 |
| Day's range | 3.8700 - 4.0199 |
| 52-week range | 3.5300 - 11.3600 |
| Volume | |
| Avg. volume | 7,432,624 |
| Market cap | 554.914M |
| Beta (5Y monthly) | 1.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.4100 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.40 |
GlobeNewswireShah Capital nominates two highly qualified independent director candidates for Novavax
Believes the two new nominated directors possess the necessary experience to tackle the underperformance of the business which will improve its share price Shah Capital which owns 6.7% of Novavax, in a letter to the board says that the low share price reflects the board and management’s failure to capitalize on Novavax’s many significant competitive advantages and TAM opportunities The letter highlights that the underperformance is self-inflicted and is the result of reactive leadership and outd
- Reuters
UPDATE 4-Novavax investor Shah Capital pushes for board shakeup
Novavax shareholder Shah Capital is pushing the vaccine maker to add two of its nominees to the board to help tackle "underperformance" at the company and improve its share price. The hedge fund nominated Suresh Katta, founder and CEO of biotech firm Saama, and Venkat Peri, CEO of Quantiva Health, to Novavax's eight-member board, saying the duo had the experience in setting the company's strategic direction.
ZacksWill Novavax's (NVAX) Strategic Reshaping Curb Cash Burn?
To extend its existing cash runway and curb cash burn, Novavax (NVAX) initiates multiple restructuring initiatives that are aimed at lowering operating expenses and enhancing profitability.
